Monoferric · DIN 02477777 · 100 mg elemental iron/mL · injection solution (Preservative-Free)
Limited Use, Reason for Use code 610 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 610 required
Write on scriptReason for Use code 610 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 610
Reason for Use code 610
For the treatment of patients with Iron Deficiency Anemia (IDA) who meet ALL the following criteria:
- Patient has documented diagnosis of IDA confirmed by laboratory testing results (e.g. hemoglobin, ferritin); AND
- Patient's IDA has experienced a failure to respond, documented intolerance, or contraindication to an adequate trial (i.e. at least 4 weeks) of at least one oral iron therapy; AND
- Patient does not have hemochromatosis or other iron storage disorders; AND
- Monoferric is administered in a setting where appropriate monitoring and management of hypersensitivity reactions can be provided to the Patient.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Ferric derisomaltose (also known as iron isomaltoside 1000)
Brand(s): Monoferric
DOSAGE FORM/ STRENGTH: 100 mg elemental iron/mL Injectable
Requests for iron derisomaltose (formerly iron isomaltoside 1000) (Monoferric) 100 mg/mL
that do not meet the Limited Use Criteria on the Ontario Drug Benefit formulary may be
considered for funding on a case-by-case basis by the EAP.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 23, record 4, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)No interchangeable product listed in the Ontario extract
Monoferric · DIN 02477777
Manufacturer: Pharmacosmos A/S; listing date 2021-02-26
Health Canada: Marketed since 2022-01-14 · brand MONOFERRIC · ATC B03AC IRON, PARENTERAL PREPARATIONS · form Solution · route Intravenous · ingredients IRON (FERRIC DERISOMALTOSE) 100 MG/ML · company Pharmacosmos a/s · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMonoferric: Formulary list price $45.00 per unit (the source does not state the unit; exact figure $45.0000). What the ministry pays, not the patient.
Ministry pays: $45.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02477777)
Source record
DIN 02477777: Monoferric
Raw flags: sec12=Y, sec3=Y
Item: 200400027; group id 246; item number 0437; lccId 00357; manufacturer id PHC
Source form: Inj Sol (Preservative-Free); strength: 100mg elemental iron/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $45.0000; ministry $45.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02477777
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96866
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02477777
Shortage record checked October 6, 2026